We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A decade ago, the bacterium Acinetobacter baumannii was identified as one of the six most common and serious multidrug-resistant pathogens, largely because of its propensity to spread in hospitals,
Amgen is laying off 200 people across its R&D organization. The latest victims of the big biotech’s ongoing pursuit of efficiency gains mainly work at its facilities in California.
Bioversys AG and Aptuit start on a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria.